MEDINCELL S.A. |
Market Closed -
Other stock markets
|
After market 03:02:01 pm | |||
| 12.66 EUR | +2.10% |
|
12.68 | +0.16% |
| Apr. 17 | Medincell: share price rises following agreement with AbbVie | CF |
| Apr. 16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.4
EUR
Average target price
16.75
EUR
Spread / Average Target
+35.08%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +75.83% | 382M | |
| +25.78% | 653B | |
| +27.00% | 556B | |
| -6.59% | 354B | |
| +20.55% | 331B | |
| +2.84% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -5.93% | 144B |
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- France's Medincell Names New Chief Medical Officer
